Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)

被引：5
|
作者：
Mignot, E.
Mayleben, D.
Fietzeet, I
机构：
来源：
LANCET NEUROLOGY | 2022年 / 21卷 / 03期
关键词：
D O I：
10.1016/S1474-4422(22)00029-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietze, I
    LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
  • [2] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
    Mignot, Emmanuel
    Mayleben, David
    Fietze, Ingo
    Leger, Damien
    Zammit, Gary
    Bassetti, Claudio L. A.
    Pain, Scott
    Kinter, Dalma Seboek
    Roth, Thomas
    LANCET NEUROLOGY, 2022, 21 (02): : 125 - 139
  • [3] Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (vol 21, pg 417, 2022)
    Knight, Pestana E. M.
    Amin, S.
    Bahi-Buisson, N.
    LANCET NEUROLOGY, 2022, 21 (07): : E7 - E7
  • [4] Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study
    Uchimura, Naohisa
    Taniguchi, Mitsutaka
    Ariyoshi, Yu
    Oka, Yasunori
    Togo, Osamu
    Uchiyama, Makoto
    SLEEP MEDICINE, 2024, 122 : 27 - 34
  • [5] Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials
    Huang, Zhaoyang
    Zhan, Shuqin
    Chen, Chunyan
    Zhang, Ruoxi
    Zhou, Yanling
    He, Jingjing
    Lin, Zhaocun
    Bao, Cungang
    Zhu, Shuangpeng
    Zhao, Jianjun
    Zhang, Shengan
    Jiang, Yu
    Wang, Yuping
    SLEEP, 2024, 47 (02)
  • [6] Itopride in functional dyspepsia:: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials
    Talley, N. J.
    Tack, J.
    Ptak, T.
    Gupta, R.
    Giguere, M.
    GUT, 2008, 57 (06) : 740 - 746
  • [7] Efficacy and safety of itopride in functional dyspepsia: Results of two phase III multicentre, randomized, double-blind, placebo-controlled trials
    Talley, Nicholas J.
    Tack, Jan
    Ptak, Theadore
    Gupta, Rajendra
    Giguere, Monique
    GASTROENTEROLOGY, 2007, 132 (04) : A93 - A93
  • [8] Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Gouni-Berthold, Ioanna
    Alexander, Veronica J.
    Yang, Qingqing
    Hurh, Eunju
    Steinhagen-Thiessen, Elisabeth
    Moriarty, Patrick M.
    Hughes, Stephen G.
    Gaudet, Daniel
    Hegele, Robert A.
    O'Dea, Louis St L.
    Stroes, Erik S. G.
    Tsimikas, Sotirios
    Witztum, Joseph L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (05): : 264 - 275
  • [9] Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
    Traboulsee, Anthony
    Greenberg, Benjamin M.
    Bennett, Jeffrey L.
    Szczechowski, Lech
    Fox, Edward
    Shkrobot, Svitlana
    Yamamura, Takashi
    Terada, Yusuke
    Kawata, Yuichi
    Wright, Padraig
    Gianella-Borradori, Athos
    Garren, Hideki
    Weinshenker, Brian G.
    LANCET NEUROLOGY, 2020, 19 (05): : 402 - 412
  • [10] Efficacy and tolerability of indiplon in adults with chronic insomnia: Results from two double-blind, placebo-controlled trials
    Klee, B.
    Keohane, D.
    Bell, J.
    Farber, R.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 : 48 - 48
12345